Comparison of Caveolin-1 and PSA in Prostate Adenocarcinoma

Objective: The aim of the present study was to evaluate caveolin-1 (CAV-1) levels as a possible alternative for the prostate specific antigen in the diagnosis of patients with prostate adenocarcinoma (PCa). Methods: The study was conducted with 33 cases (mean age 67.2 (45-90) years) and 16 control patients (mean age 56.68 (48-77) years). Blood sample solution results of both the groups were read twice, and the average optical density of the zero standard was subtracted from the solution results’ average. Results: The average levels of prostate-specific antigen (PSA) were 1.1 (±0.64) for the control group and 12.3 (±8.7) for patients with adenocarcinoma. The average levels of CAV-1 were 336 (±41.1) in the control group and 476 (±66.9) in patients with adenocarcinoma. PCa was detected in 33 patients, 27 of whom underwent prostatectomy, and the remaining 6 began hormonotherapy. Of these 33 patients, 2 had a Gleason score of 4, 16 had a Gleason score of 6, 10 had a Gleason score of 7, 3 had a Gleason score of 8, and 2 had a Gleason score of 9. Patients with PCa had higher PSA and CAV-1 than the control group (p

Prostat Adenokarsinomunda Caveolin-1 ve PSA'nın Karşılaştırılması

Amaç: Bu çalışmanın amacı prostat adenokarsinomu (PCa) olan hastaların tanısında prostat spesifik antijen (PSA) için olası bir alternatif olarak Caveolin-1 (CAV-1) seviyelerini değerlendirmektir. Yöntemler: Çalışma 33 hasta ve 16 kontrol grubu olmak üzere iki gruba ayrılmıştır. Her iki grubun kan örneklerinden ELİSA kiti ile CAV-1 düzeyleri çalışıldı. Sonuçlar tanı öncesi PSA düzeyi ile karşılaştırılarak istatistiksel olarak analiz edildi. Bulgular: Çalışmada hasta grubunun yaş ortalaması 67,2 (45-90) iken kontrol grubunu ortalama yaşı 56,68 (48-77) idi. PSA ortalaması kontrol grubu için 1,1 (±0,64), adenokarsinomalı hastalar için 12,3 (±8,7) idi. Kontrol grubunda ortalama CAV-1 düzeyi 336 (±41,1), adenokarsinomalı hastalarda ise 476 (±66,9) idi. Hastaların 27'sine prostatektomi yapıldı, geriye kalan 6'sına ise hormonoterapiye başlandı. Bu 33 hastadan 18’inin Gleason Skoru (GS) 6 ve altında, 10'u GS 7, 3'ünün GS 8 ve 2'si GS 9 idi. Prostat adenokarsinomu olan grupta daha yüksek PSA ve CAV-1 düzeyleri saptandı (p

Kaynakça

1. Rosai J. (2004) Rosai and Ackerman's Surgical Pathology. (9. baskı) Chapter 18, Male Reproductive System. Elsevier Inc. 1361-411.

2. Epstein JI, Kumar V, Abbas AK, Fausto N. (2005). The Lower Urinary Tract and Male Genital System. (7. baskı) Chapter 21. Robbins and Cotran PathologicDisease. Philadelphia: Elsevier Saunders. 1023-58.

3. Walsh PC, Retik BA, Vaughan ED, Wein AJ. Campbell's urology. 9th ed. Philadelphia: Saunders Co., 2007: 3001-221.

4. Hernandez J, Thompson IM. prostate-specific antigen a review of the validation of the most commoly used cancer biomarker. Cancer 2004; 101: 894-904. [CrossRef]

5. Corn PG, Thompson TC. Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Cancer Manag Res 2010; 10: 111-22. [CrossRef]

6. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005; 288: 494-506. [CrossRef]

7. Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane BF. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci 2005; 118: 1493-503 [CrossRef]

8. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin–1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 1999; 59: 5719-23.

9. Chang WS, Lin SS, Li FJ, Tsai CW, Li LY, Lien CS, et al. Significant association of caveolin-1 (CAV1) genotypes with upper urothelial tract cancer. Anticancer Res 2013; 33: 4907-12.

10. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, et al. Secreted caveolin–1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61: 3882-5.

11. Bartz R, Zhou J, Hsieh JT, Ying Y, Li W, Liu P. Caveolin–1 secreting LNCaP cells induce tumor growth of caveolin–1 negative LNCaP cells in vivo. Int J Cancer 2008; 122: 520-5. [CrossRef]

12. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003; 23: 9389-404. [CrossRef]

13. Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, et al. Tumor cell-secreted caveolin–1 has proangiogenic activities in prostate cancer. Cancer Res 2008; 68: 731-9. [CrossRef]

14. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, et al. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res 2006; 12: 4872-5. [CrossRef]

15. Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol 2014; 25: 47-60. [CrossRef]

16. Bray F, Sankila R, Ferlay J, Parkin DM.Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166. [CrossRef]

17. Tahir SA, Ren C, Timme TL, Gdor Y, Hoogeveen R, Morrisett JD, et al. Development of an immunoassay for serum caveolin–1: a novel biomarker for prostate cancer. Clin Cancer Res 2003; 9: 3653-9.

18. Raventós CX, Orsola A, de Torres I, Cecchini L, Trilla E, Planas J, et al. Preoperative Prediction of Pathologically Insignificant Prostate Cancer in Radical Prostatectomy Specimens: The Role of Prostate Volume and the Number of Positive Cores. Urol Int 2010; 84: 153-8. [CrossRef]

19. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 Expression in Clinically Confined Human Prostate Cancer: A Novel Prognostic Marker1. Cancer Research 1999; 59: 5719-23.

20. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, et al. Preoperative Serum Caveolin-1 as a Prognostic Marker for Recurrence in a Radical Prostatectomy Cohort. Clin Cancer Res 2006; DOI: 10.1158/1078-0432.CCR-06-0417. [CrossRef]

21. Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, et al. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J Pathol 2013; 231: 77-87. [CrossRef]

22. Luo B, Wang AL. An update of the markers for prostate cancer. Zhonghua Nan Ke Xue 2010; 16: 531-5.

Kaynak Göster

  • ISSN: 2146-6505
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 2011
  • Yayıncı: Galenos Yayınevi

4.5b 3.2b